- Revelation Biosciences Inc. announced the **immediate exercise of certain outstanding warrants**, generating **$9.6 million in gross proceeds**.  **[1810560_0001193125-25-203750_revb-ex99_1.htm:0]** **[1810560_0001193125-25-203750_revb-20250911.htm:1]** 
- The transaction involved the exercise of **4,355,000 shares of common stock** at an exercise price of **$2.20 per share**.  **[1810560_0001193125-25-203750_revb-ex99_1.htm:0]** **[1810560_0001193125-25-203750_revb-20250911.htm:1]** 
- In consideration for the immediate cash exercise, the exercising holders will receive **new Class I warrants** to purchase up to **13,065,000 shares of common stock** at an exercise price of **$2.20 per share**, exercisable for five years after stockholder approval.  **[1810560_0001193125-25-203750_revb-ex99_1.htm:0]** **[1810560_0001193125-25-203750_revb-20250911.htm:1]** 
- The company intends to use the net proceeds from the warrant exercises for its **clinical development plans, working capital, and general corporate purposes**.  **[1810560_0001193125-25-203750_revb-20250911.htm:1]**

REVELATION BIOSCIENCES (REVB)